Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation

Cancer Letters

Volumn 290, Issue 2, 2010, Pages 182-191

  Lu, Zhongzheng ^a   Jin, Yanli ^a   Qiu, Lin ^b   Lai, Yingrong ^a   Pan, Jingxuan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b Harbin Institute of Hematology and Oncology   (China)

Author keywords

Apoptosis; Bcr Abl; Celastrol; CML; Imatinib; T315I mutation

Indexed keywords

BCR ABL PROTEIN; CELASTROL; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; ISOLEUCINE; MUTANT PROTEIN; TANESPIMYCIN; THREONINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MALE; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; TUMOR XENOGRAFT; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SEPARATION; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MICE; MICE, NUDE; MUTATION; NEOPLASMS, EXPERIMENTAL; PIPERAZINES; PYRIMIDINES; SIGNAL TRANSDUCTION; TRITERPENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 77649178833     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.09.006     Document Type: Article

References (37)

1. Weinstein I.B., and Joe A. Oncogene addiction. Cancer Res. 68 (2008) 3077-3080
2. Sharma S.V., and Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 21 (2007) 3214-3231
3. Chen R., Gandhi V., and Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res. 66 (2006) 10959-10966
4. Cortez D., Kadlec L., and Pendergast A.M. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol. Cell. Biol. 15 (1995) 5531-5541
5. Druker B.J., Guilhot F., O'Brien S., and Larson R.A. Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): the five-year update from the IRIS study. J. Clin. Oncol. 24 (2006) 18S (Abstract)
6. Bellodi C., Lidonnici M.R., Hamilton A., Helgason G.V., Soliera A.R., Ronchetti M., Galavotti S., Young K.W., Selmi T., Yacobi R., Van Etten R.A., Donato N., Hunter A., Dinsdale D., Tirro E., Vigneri P., Nicotera P., Dyer M.J., Holyoake T., Salomoni P., and Calabretta B. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J. Clin. Invest. 119 (2009) 1109-1123
7. Hofmann W.K., Jones L.C., and Lemp N.A. S. de Vos, H. Gschaidmeier, D. Hoelzer, O.G. Ottmann, and H.P. Koeffler, Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 99 (2002) 1860-1862
8. Donato N.J., Wu J.Y., Stapley J., Gallick G., Lin H., Arlinghaus R., and Talpaz M. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101 (2003) 690-698
9. Gambacorti-Passerini C., Gambacorti-Passerini C., le Coutre P., Zucchetti M., and D'Incalci M. Binding of imatinib by alpha(1)-acid glycoprotein. Blood 100 (2002) 367-368
10. Thomas J., Wang L., Clark R.E., and Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104 (2004) 3739-3745
11. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., and Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 (2001) 876-880
12. Hochhaus A., Kreil S., Corbin A.S., La Rosee P., Muller M.C., Lahaye T., Hanfstein B., Schoch C., Cross N.C., Berger U., Gschaidmeier H., Druker B.J., and Hehlmann R. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16 (2002) 2190-2196
13. Tanaka R., and Kimura S. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation. Expert. Rev. Anticancer Therap. 8 (2008) 1387-1398
14. Talpaz M., Shah N.P., Kantarjian H., Donato N., Nicoll J., Paquette R., Cortes J., O'Brien S., Nicaise C., Bleickardt E., Blackwood-Chirchir M.A., Iyer V., Chen T.T., Huang F., Decillis A.P., and Sawyers C.L. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354 (2006) 2531-2541
15. Gumireddy K., Baker S.J., Cosenza S.C., John P., Kang A.D., Robell K.A., Reddy M.V., and Reddy E.P. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc. Natl. Acad. Sci. USA 102 (2005) 1992-1997
16. Quintas-Cardama A., Kantarjian H., and Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat. Rev. Drug. Discov. 6 (2007) 834-848
17. Zhang H., Trachootham D., Lu W., Carew J., Giles F.J., Keating M.J., Arlinghaus R.B., and Huang P. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia 22 (2008) 1191-1199
18. Chandra J., Tracy J., Loegering D., Flatten K., Verstovsek S., Beran M., Gorre M., Estrov Z., Donato N., Talpaz M., Sawyers C., Bhalla K., Karp J., Sausville E., and Kaufmann S.H. Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood 107 (2006) 2501-2506
19. Gorre M.E., Ellwood-Yen K., Chiosis G., Rosen N., and Sawyers C.L. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 100 (2002) 3041-3044
20. Peng C., Brain J., Hu Y., Goodrich A., Kong L., Grayzel D., Pak R., Read M., and Li S. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood 110 (2007) 678-685
21. Nimmanapalli R., Fuino L., Bali P., Gasparetto M., Glozak M., Tao J., Moscinski L., Smith C., Wu J., Jove R., Atadja P., and Bhalla K. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 63 (2003) 5126-5135
22. Shi X., Jin Y., Cheng C., Zhang H., Zou W., Zheng Q., Lu Z., Chen Q., Lai Y., and Pan J. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Clin. Cancer Res. 15 (2009) 1686-1697
23. Whitesell L., and Lindquist S.L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 5 (2005) 761-772
24. Nimmanapalli R., O'Bryan E., and Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res. 61 (2001) 1799-1804
25. Hieronymus H., Lamb J., Ross K.N., Peng X.P., Clement C., Rodina A., Nieto M., Du J., Stegmaier K., Raj S.M., Maloney K.N., Clardy J., Hahn W.C., Chiosis G., and Golub T.R. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 10 (2006) 321-330
26. Zhang T., Hamza A., Cao X., Wang B., Yu S., Zhan C.G., and Sun D. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol. Cancer Therapeut. 7 (2008) 162-170
27. Qiu L., Wang X.D., Yu B.H., Lu R.Z., Ge F., Wang X.L., Chen L.J., Han B.H., Zhan Z.M., Zhang B.L., and Ma J. Effect of a novel tyrosine kinase inhibitor HHGV678 on growth inhibition of Bcr-Abl wild type and IM-resistant cell lines in vitro. Zhongguo Shi Yan Xue Ye Xue Za Zhi 16 (2008) 1039-1043
28. Jin Y., Chen Q., Shi X., Lu Z., Cheng C., Lai Y., Zheng Q., and Pan J. Activity of triptolide against human mast cells harboring the kinase domain mutant KIT. Cancer Sci. 100 (2009) 1335-1343
29. Jin Y., Chen Q., Shi X., Lu Z., Cheng C., Lai Y., Zheng Q., and Pan J. Activity of triptolide against human mast cells harboring the kinase domain mutant KIT. Cancer Sci. (2009)
30. Pan J., Quintas-Cardama A., Kantarjian H.M., Akin C., Manshouri T., Lamb P., Cortes J.E., Tefferi A., Giles F.J., and Verstovsek S. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood 109 (2007) 315-322
31. Gotlib J., Berube C., Growney J.D., Chen C.C., George T.I., Williams C., Kajiguchi T., Ruan J., Lilleberg S.L., Durocher J.A., Lichy J.H., Wang Y., Cohen P.S., Arber D.A., Heinrich M.C., Neckers L., Galli S.J., Gilliland D.G., and Coutre S.E. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 106 (2005) 2865-2870
32. Yang H., Chen D., Cui Q.C., Yuan X., and Dou Q.P. Celastrol, a triterpene extracted from the Chinese, Thunder of God Vine, is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res. 66 (2006) 4758-4765
33. Corson T.W., and Crews C.M. Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell 130 (2007) 769-774
34. Efferth T., Li P.C., Konkimalla V.S., and Kaina B. From traditional Chinese medicine to rational cancer therapy. Trends Mol. Med. 13 (2007) 353-361
35. Tao X.L., Sun Y., Dong Y., Xiao Y.L., Hu D.W., Shi Y.P., Zhu Q.L., Dai H., and Zhang N.Z. A prospective, Controlled, double-blind, cross-over study of tripterygium wilfodii hook F in treatment of rheumatoid arthritis. Chin. Med. J. Engl. 102 (1989) 327-332
36. Sethi G., Ahn K.S., Pandey M.K., and Aggarwal B.B. Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood 109 (2007) 2727-2735
37. Abbas S., Bhoumik A., Dahl R., Vasile S., Krajewski S., Cosford N.D., and Ronai Z.A. Preclinical studies of celastrol and acetyl isogambogic acid in melanoma. Clin. Cancer Res. 13 (2007) 6769-6778